Nugenerex Immuno-oncology, Inc. Increase (Decrease) in Interest Payable, Net
Nugenerex Immuno-oncology, Inc. reported Increase (Decrease) in Interest Payable, Net of $749.49 thousand for the 9-month period ending 2021-04-30, per its 10-Q filed 2021-06-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2021-06-14
- Nugenerex Immuno-oncology, Inc. increase (decrease) in interest payable, net for the quarter ending 2021-04-30 was $261.07K, a 19.56% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in interest payable, net for the quarter ending 2021-01-31 was $249.66K, a 19.56% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in interest payable, net for the quarter ending 2020-10-31 was $238.76K, a 19.56% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in interest payable, net for the quarter ending 2020-07-31 was $228.33K, a 19.56% increase year-over-year.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in interest payable, net for fiscal 2020 was $855.20K, a 19.56% increase from fiscal 2019.
- Nugenerex Immuno-oncology, Inc. increase (decrease) in interest payable, net for fiscal 2019 was $715.27K.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|
| 2021-04-30 | $261.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | $510.73K derived: sum of 2 quarters · filed 2021-06-14 | $749.49K 10-Q · filed 2021-06-14 | $977.82K derived: sum of 4 quarters · filed 2021-06-14 |
| 2021-01-31 | $249.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-12 | $488.42K 10-Q · filed 2021-03-12 | $716.75K derived: sum of 3 quarters · filed 2021-03-12 | $935.11K derived: sum of 4 quarters · filed 2021-06-14 |
| 2020-10-31 | $238.76K 10-Q · filed 2020-12-15 | $467.09K derived: sum of 2 quarters · filed 2020-12-15 | $685.44K derived: sum of 3 quarters · filed 2021-06-14 | $894.26K derived: sum of 4 quarters · filed 2021-06-14 |
| 2020-07-31 | $228.33K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29 | $446.68K derived: sum of 2 quarters · filed 2021-06-14 | $655.50K derived: sum of 3 quarters · filed 2021-06-14 | $855.20K 10-K · filed 2020-10-29 |
| 2020-04-30 | $218.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | $427.17K derived: sum of 2 quarters · filed 2021-06-14 | $626.87K 10-Q · filed 2021-06-14 | $817.84K derived: sum of 4 quarters · filed 2021-06-14 |
| 2020-01-31 | $208.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-12 | $408.51K 10-Q · filed 2021-03-12 | $599.48K derived: sum of 3 quarters · filed 2021-03-12 | $782.11K derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-10-31 | $199.69K 10-Q · filed 2020-12-15 | $390.67K derived: sum of 2 quarters · filed 2020-12-15 | $573.29K derived: sum of 3 quarters · filed 2020-12-15 | |
| 2019-07-31 | $190.97K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29 | $373.60K derived: sum of 2 quarters · filed 2020-10-29 | $715.27K 10-K · filed 2020-10-29 | |
| 2019-04-30 | $182.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-19 | $524.30K 10-Q · filed 2020-06-19 | ||
| 2019-01-31 | $341.68K 10-Q · filed 2020-06-17 |